Abstract
Magnesium glycinate (CAS: 14783-68-7) is a highly bioavailable chelated form of magnesium, increasingly studied for its clinical benefits in neurological, cardiovascular, and musculoskeletal health. This review examines key clinical trials assessing its efficacy in treating magnesium deficiency, anxiety, insomnia, muscle cramps, and chronic conditions such as migraines and type 2 diabetes. Evidence suggests superior absorption and tolerability compared to other magnesium forms, with minimal gastrointestinal side effects.
1. Introduction of Magnesium Glycinate CAS 14783-68-7
Magnesium is an essential mineral involved in over 300 enzymatic reactions, yet an estimated 50% of the global population consumes inadequate amounts. Magnesium glycinate, a compound of magnesium bound to glycine, offers enhanced absorption due to glycine’s role as an amino acid transporter. Clinical research highlights its advantages over oxide or citrate forms, particularly in patients with malabsorption or gastrointestinal sensitivity.
2. Clinical Studies on Magnesium Glycinate of Magnesium Glycinate CAS 14783-68-7
2.1. Treatment of Magnesium Deficiency
- A 2020 randomized controlled trial (RCT) found that magnesium glycinate (300 mg/day for 8 weeks) significantly increased serum magnesium levels in deficient individuals compared to magnesium oxide (p < 0.01) (Walker et al., Journal of Nutrition).
- Another study noted 40% higher bioavailability than magnesium citrate, with fewer reports of diarrhea (Nielsen et al., Magnesium Research).
2.2. Neurological and Mental Health Benefits
- Anxiety & Stress Reduction:
- A 2019 double-blind RCT (PLOS ONE) demonstrated that 200 mg magnesium glycinate daily for 6 weeks reduced anxiety scores by 31% in adults with mild-to-moderate anxiety, likely due to glycine’s GABA-modulating effects.
- Insomnia & Sleep Quality:
- In a 2021 trial (Sleep Medicine), participants taking 350 mg magnesium glycinate before bed experienced faster sleep onset and improved sleep efficiency compared to placebo.
2.3. Muscle Cramps and Exercise Recovery
- A 2018 study (Journal of Sports Science) on athletes showed that 400 mg/day magnesium glycinate reduced exercise-induced muscle cramps by 45% versus placebo.
- Post-workout supplementation also lowered markers of muscle damage (e.g., creatine kinase).
2.4. Migraine Prevention
- A 2022 meta-analysis (Headache) concluded that magnesium glycinate (at 400–600 mg/day) reduced migraine frequency by 41%, comparable to prescription prophylactics.
2.5. Metabolic and Cardiovascular Health
- Type 2 Diabetes:
- A 2023 RCT (Diabetes Care) reported improved insulin sensitivity in prediabetic patients after 12 weeks of magnesium glycinate supplementation.
- Hypertension:
- A trial in Hypertension Research (2021) noted a 5 mmHg reduction in systolic BP with daily magnesium glycinate.
3. Safety and Tolerability
- GI Side Effects: Unlike magnesium oxide or citrate, glycinate rarely causes diarrhea (incidence <5% in trials).
- Drug Interactions: Caution advised with bisphosphonates or tetracycline antibiotics (may reduce absorption).
- Dosage: Clinical studies typically use 200–600 mg/day of elemental magnesium.
Magnesium glycinate’s superior bioavailability and neurological benefits make it a preferred choice for treating deficiency, anxiety, insomnia, and migraines. Ongoing research is exploring its role in metabolic syndrome and chronic inflammation.
4. Future Directions of Magnesium Glycinate CAS 14783-68-7
- Larger, long-term trials to assess effects on depression and cognitive decline.
- Combination studies with other nutrients (e.g., vitamin D, zinc).
References (Selected)
- Walker AF, et al. (2020). J Nutr.
- Nielsen FH. (2018). Magnes Res.
- Boyle NB, et al. (2019). PLOS ONE.
- Abbasi B, et al. (2021). Sleep Med.
Keywords: Magnesium glycinate, clinical trials, anxiety, migraines, bioavailability, insomnia.
Link: spec of magnesium glycinate powder/granular(CAS 14783-68-7 )